This trial will investigate if ASN008, a topical treatment, can help reduce itch in people with eczema. Participants will use ASN008 or placebo cream to see which works best.
- Atopic Dermatitis
1 Primary · 4 Secondary · Reporting Duration: Baseline to Day 56
4 Treatment Groups
1 of 4
1 of 4
1 of 4
ASN008 Matching Vehicle
1 of 4
120 Total Participants · 4 Treatment Groups
Primary Treatment: ASN008 2.5% · Has Placebo Group · Phase 2
Who is running the clinical trial?
Age 18+ · All Participants · 8 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is ASN008 1.25% a secure option for medical consumers?
"Our team has assigned ASN008 1.25% a score of 2 on the safety scale due to its status as a Phase 2 trial, in which some data exists regarding safety but none that can be used to confirm efficacy." - Anonymous Online Contributor
Are there any current opportunities to take part in this experiment?
"Per the details listed on clinicaltrials.gov, this study is currently recruiting research subjects. The trial was first posted on May 3rd 2023 and its information was most recently updated a little over a week later, on May 12th of the same year." - Anonymous Online Contributor
What is the current capacity for participant enrollment in this clinical trial?
"Affirmative. Clinicaltrials.gov reports that this research endeavor, which was first posted on May 3rd 2023, is actively recruiting individuals to participate. In total, 120 participants need to be drawn from 13 separate clinical trial sites." - Anonymous Online Contributor
How many facilities is this experiment managed across?
"This medical trial is running out of 15 different sites, including TrialSpark Investigative Site 0118 in Hot Springs, Arkansas, TrialSpark Investigative Site 0101 in Los Angeles, California and TrialSpark Investigative Site 0103 in Miami Lakes Florida." - Anonymous Online Contributor